What are the indications, target laboratory goals, dosing schedule, contraindications, and alternatives for therapeutic phlebotomy?

Therapeutic Phlebotomy

Therapeutic phlebotomy is the first-line treatment for hereditary hemochromatosis, polycythemia vera, porphyria cutanea tarda, and select cases of secondary erythrocytosis, with specific target ferritin levels of 50 μg/L for induction and 50-100 μg/L for maintenance in hemochromatosis. 1

Primary Indications

The established indications for therapeutic phlebotomy include:

• Hereditary hemochromatosis (HFE-related and non-HFE variants)
• Polycythemia vera
• Porphyria cutanea tarda
• Secondary erythrocytosis (COPD, post-renal transplant, congenital cyanotic heart disease) 2, 3
• Sickle cell disease (select cases)
• Nonalcoholic fatty liver disease with hyperferritinemia 2

Target Laboratory Goals

For Hemochromatosis:

Induction Phase:

• Target serum ferritin: 50 μg/L 1
• Monitor hemoglobin at each session; maintain >12 g/dL 1
• Check ferritin monthly or after every 4th phlebotomy 1
• When ferritin drops below 200 μg/L, measure every 1-2 sessions 1

Maintenance Phase:

• Target serum ferritin: 50-100 μg/L 1
• More relaxed targets acceptable in elderly: <200 μg/L (women), <300 μg/L (men) 1
• Monitor ferritin every 6 months 1
• Aim for transferrin saturation <50-60% (though evidence-based targets lacking) 1

For Polycythemia:

• Target hematocrit: <45% for polycythemia vera 4
• Target hematocrit: <52% for secondary polycythemia 4

Dosing Schedule

Volume and Frequency:

Induction Phase:

• Volume: 400-500 mL per session (adjust for body weight and tolerance) 1
• Frequency: Weekly to every 2 weeks 1
• Alternative protocol: 350 mL every 3 days until target reached 4

Maintenance Phase:

• Frequency: Every 1-4 months depending on iron status 1
• Average ferritin rise without treatment: ~100 μg/L per year 1

Critical Monitoring Parameters:

Hemoglobin thresholds requiring action:

• <12 g/dL: Decrease phlebotomy frequency, consider volume reduction 1
• <11 g/dL: Discontinue phlebotomy immediately, reassess with blood tests and clinical evaluation 1

This is a crucial safety measure—anemia is not characteristic of hemochromatosis, and its presence should trigger investigation for other causes 1.

Contraindications and Precautions

Relative Contraindications:

• Hemoglobin <11 g/dL (absolute contraindication to proceed) 1
• Inaccessible veins (consider alternatives) 1
• Severe needle phobia 1
• Concomitant anemia from other causes 1
• Hemodynamic instability (cardiac impairment) 1
• Advanced liver disease (if considering chelation alternatives) 1

Special Populations:

Elderly patients: Poorly tolerate aggressive ferritin targets of 50 μg/L during maintenance; use more relaxed targets 1

Juvenile hemochromatosis with cardiac involvement: May require combined therapy with chelation due to life-threatening cardiac iron overload 1

Monitoring for Complications:

• Check plasma folate and cobalamin periodically, especially with numerous venesections; supplement if necessary 1
• Avoid overtreatment leading to iron deficiency (ferritin <20 μg/L increases dietary iron absorption significantly) 1
• Adverse event rate is low (4.3% of procedures), primarily vasovagal reactions, comparable to healthy blood donors 5

Alternatives to Phlebotomy

When phlebotomy is not feasible or cannot be performed at desired frequency:

Second-Line Options:

Erythrocytapheresis: Consider when available 1

Iron Chelation Therapy:

• Deferoxamine (DFO): Parenteral administration, limited experience in hemochromatosis 1
• Deferasirox (DFX): Oral, 10-15 mg/kg dosing
  • Reduced median ferritin by 75% over 48 weeks 1
  • Not approved by European Medicines Agency for hemochromatosis 1
  • Contraindicated in advanced liver disease 1
  • Side effects: GI symptoms, renal impairment 1
• Deferiprone (DFP): Oral, very limited experience
  • Risk of hematological toxicity including agranulocytosis 1

All chelation drugs contraindicated in pregnancy and require dose adjustment in renal failure 1

Combined Approach:

For patients with advanced disease poorly tolerating standard phlebotomy:

• Personalized mini-phlebotomies plus subcutaneous deferoxamine infusion 1
• Refer to specialized centers for evaluation 1

Dietary Modifications (Adjunctive, Not Substitute)

• Avoid iron supplementation and iron-fortified foods 1
• Avoid supplemental vitamin C, especially before iron depletion 1
• Limit red meat consumption 1
• Restrict alcohol intake during iron depletion; abstain completely if cirrhosis present 1
• Consume citrus fruits/juices in moderation, not with other foods 1

Common Pitfalls to Avoid

1. Over-aggressive depletion: Ferritin <20 μg/L causes symptomatic iron deficiency and increased dietary iron absorption 1
2. Inadequate monitoring: Ferritin should be checked monthly during induction, then every 1-2 sessions when <200 μg/L 1
3. Ignoring hemoglobin: Always check before each session; discontinue if <11 g/dL 1
4. Sending patients to "just donate blood": TP requires prescribed course with specific targets and monitoring 6
5. Unexpected ferritin fluctuations: Always investigate—not characteristic of hemochromatosis 1